Investigational drug · Phase 2
GDC-1261
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Prostate Cancer, Metastatic Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "GDC-1261"
First trial start
2026
Apr 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GDC-1261", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Prostate Cancer
- Metastatic Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "GDC-1261" as an intervention, largest first.
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07567846 · 260 participants (planned) · Start Apr 29, 2026 · Primary completion Nov 30, 2027
Drug: GDC-1261 · For: Advanced Prostate Cancer; Metastatic Prostate Cancer
Sites: Scottsdale, Arizona; New Haven, Connecticut; Nashville, Tennessee · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Prostate Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- XNW5004EZH2iPhase 37 trials
Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Teverelix DPPhase 23 trials
Antev Ltd. · Acute Urinary Retention, Benign Prostate Hypertrophy(BPH), Endometriosis Pelvic
- QLH12016Phase 22 trials
Qilu Pharmaceutical Co., Ltd. · Prostatic Neoplasms, Advanced Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.